API SUPPLIERS

API Suppliers

2

US DMFs Filed

2

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

RadioMedix

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

RadioMedix and Orano Med Receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors

Details:

AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy, being developed for treatment of adults with unresectable/metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.

Lead Product(s): Alphamedix

Therapeutic Area: Oncology Product Name: AlphaMedix

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Oranomed

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 12, 2024

ASK
US

Upload
your Marketing & Sales content

RadioMedix

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

Details:

AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitting particles.

Lead Product(s): Alphamedix

Therapeutic Area: Oncology Product Name: AlphaMedix

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Oranomed

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2023

ASK
US

Upload
your Marketing & Sales content

RadioMedix

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Platform and Diagnostic Companion Radiopharmac...

Details:

The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuroendocrine tumors.

Lead Product(s): Alphamedix

Therapeutic Area: Oncology Product Name: AlphaMedix

Highest Development Status: Phase IIProduct Type: Peptide

Partner/Sponsor/Collaborator: Portland Investment Counsel Inc.

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing October 07, 2022

ASK
US

Upload
your Marketing & Sales content